Jul 02,2021

Electronic patient‑reported outcomes and machine learning in predicting immune‑related adverse events of immune checkpoint inhibitor therapies

Deep learning systems have widely presented promising results in cancer diagnostics and for Kaiku Health, machine learning (ML) based approaches are not anything new. Previously, Oulu University Hospital (OYS) and Kaiku Health have shown that it is possible to predict both symptom and adverse event onset and continuation in patients receiving immune checkpoint inhibitor (ICI) therapies. In a previous study, the company investigated whether machine learning could be used to predict the treatment response, or more specifically objective response rate (ORR) of ICI-treated patients, based on clinical and patient-reported data.

PRODUCT

#platform

#ml

View Analyst & Ambassador Comments
Go to original news
Jul 08,2021

Disparities in access to mobile devices and e-health literacy among breast cancer survivors

The number of e-health interventions developed for breast cancer survivors continues to increase. However, issues with engagement and retention are common. This study aimed to explore e-health literacy rates and access to smartphones and tablets in a large sample of breast cancer survivors.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 22,2021

Artificial Intelligence Models to Analyze Cancer Images Take Shortcuts that Introduce Bias

Artificial intelligence tools and deep learning models are a powerful tool in cancer treatment. They can be used to analyze digital images of tumor biopsy samples, helping physicians quickly classify the type of cancer, predict prognosis and guide a course of treatment for the patient. However, unless these algorithms are properly calibrated, they can sometimes make inaccurate or biased predictions. A new study led by researchers from the University of Chicago shows that deep learning models trained on large sets of cancer genetic and tissue histology data can easily identify the institution that submitted the images.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 15,2021

Collaboration Between AbbVie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Diseas

The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. These genetic data have been paired with detailed health information to create this browsable resource.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Jul 05,2021

The role of teledentistry in oral cancer patients during the COVID-19 pandemic: an integrative literature review

This integrative review aimed to assess the benefits of the use of teledentistry for patients undergoing treatment of oral and head and neck cancer during the COVID-19 pandemic.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Jul 13,2021

A hybrid method of healthcare delivery research and human-centered design to develop technology-enabled support for caregivers of hematopoietic stem cell transplant recipients

Health information technology (HIT) is a widely recognized strategy to encourage cancer patients and caregivers to participate in healthcare delivery in a sustainable and cost-effective way. In the context of autologous hematopoietic cell transplant (HSCT), HIT-enabled tools have the potential to effectively engage, educate, support, and optimize outcomes of patients and caregivers in the outpatient setting. This study sought to leverage human-centered design to develop a high-fidelity prototype of a HIT-enabled psychoeducational tool for HSCT caregivers.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 25,2021

Improvements in strength and agility measures of functional fitness following a telehealth-delivered home-based exercise intervention in endometrial cancer survivors

Endometrial cancer is strongly linked to obesity and inactivity; however, increased physical activity has important benefits even in the absence of weight loss. Resistance (strength) training can deliver these benefits; yet few women participate in resistance exercise. The purpose of this study was to describe both physiological and functional changes following a home-based strength training intervention.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Jul 27,2021

Acceptance- and mindfulness-based techniques for physical activity promotion in breast cancer survivors: a qualitative study

The purpose of this study was to develop and characterize the relevance and potential utility of an electronically delivered acceptance- and mindfulness-based approaches to physical activity promotion for insufficiently active breast cancer survivors. The acceptance- and mindfulness-based physical activity intervention was delivered to participants electronically over the course of 4–8 weeks.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 06,2021

OncoHost’s Focus on the Patient Offers Precision Oncology to Combat Cancer

Cancer treatment is often, fittingly, about the cancer itself. Many treatments try to attack the cancerous cells or at least stimulate a stronger response so that the immune system is better able to fight a tumor. Israeli company OncoHost takes a different approach. Founded in 2017, OncoHost focuses on the host response to cancer therapy, seeking to personalize and modify care rather than develop new treatments.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jul 16,2021

COTA and MedStar Health Partner To Drive Scientific Research and Expedite Delivery of Innovative Cancer Treatments

COTA, Inc., an oncology real-world data and analytics company, announced a new research partnership with MedStar Health. COTA will support MedStar Health in its use of real-world data to accelerate scientific discovery and improve care for cancer patients. COTA provides comprehensive oncology real-world data abstraction, curation, and analytics capabilities to leading healthcare provider organizations and life sciences companies that are caring and developing treatments for patients living with a wide range of cancers.

COLLABORATION PARTNERSHIP

#institution

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY